Zhong-sheng S. Tong
Tianjin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Dynamic changes in peripheral B and NK cells reflect treatment response in breast cancer subtypes.
Journal: Discover oncology
Published: December 03, 2025
Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.
Journal: BMC cancer
Published: September 19, 2025
OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 26, 2025
Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option☆.
Journal: ESMO open
Published: February 05, 2025
Co-Expression of MHC-II and ANXA1: Mediators of PD-1/PD-L1 Therapy Resistance in Breast Cancer.
Journal: Cancer reports (Hoboken, N.J.)
Published: July 17, 2024
Gemcitabine long-term maintenance chemotherapy benefits patients with survival: a multicenter, real-world study of advanced breast cancer treatment in China
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: March 18, 2024
ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance.
Journal: Discover oncology
Published: May 06, 2023
Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study.
Journal: Frontiers in oncology
Published: June 27, 2022
Age at initial diagnosis and prognosis of breast cancer: a nationwide multicenter retrospective study in China.
Journal: Annals of translational medicine
Published: January 15, 2022
Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China.
Journal: Journal of oncology
Published: November 23, 2020
Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study
Journal: Zhonghua yi xue za zhi
Published: August 15, 2020
Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 22, 2020
Last Updated: 09/26/2026